---
title: Azithromycin
aliases: ['Zithromax', 'Zmax', 'Azythromycin']
date: "27-10-2025"
updated: "27-10-2025"
---

<Callout>
Azalide macrolide antibiotic with a broad spectrum of activity.
</Callout>

## Indication

- **community-acquired pneumonia (CAP)**
- **Acute bacterial sinusitis**.
- **Acute otitis media**
- Uncomplicated **skin and skin structure infections**.
- **Chlamydia trachomatis** infections (urethritis and cervicitis).
- **pharyngitis/tonsillitis**
- **Genital ulcer disease** (*Haemophilus ducreyi* - chancroid).

## Dose

### Adult Dosage

<Table>
  <TableHeader>
    <TableRow>
      <TableHead>Indication</TableHead>
      <TableHead>Dose</TableHead>
      <TableHead>Frequency</TableHead>
      <TableHead>Notes/Duration</TableHead>
    </TableRow>
  </TableHeader>
  <TableBody>
    <TableRow>
      <TableCell>CAP, Pharyngitis/Tonsillitis, Uncomplicated Skin/Skin Structure</TableCell>
      <TableCell>500 mg</TableCell>
      <TableCell>Once daily</TableCell>
      <TableCell>Day 1, followed by 250 mg once daily on Days 2–5 (total 5 days)</TableCell>
    </TableRow>
    <TableRow>
      <TableCell>Acute Bacterial Sinusitis, COPD Exacerbations</TableCell>
      <TableCell>500 mg</TableCell>
      <TableCell>Once daily</TableCell>
      <TableCell>For 3 days</TableCell>
    </TableRow>
    <TableRow>
      <TableCell>Non-gonococcal Urethritis/Cervicitis (*C. trachomatis*)</TableCell>
      <TableCell>1 g</TableCell>
      <TableCell>Single dose</TableCell>
      <TableCell>Maximum single dose</TableCell>
    </TableRow>
    <TableRow>
      <TableCell>Gonococcal Urethritis/Cervicitis (*N. gonorrhoeae*)</TableCell>
      <TableCell>2 g</TableCell>
      <TableCell>Single dose</TableCell>
      <TableCell>Maximum single dose</TableCell>
    </TableRow>
  </TableBody>
</Table>

### Paediatric Dosage (6 months and older)

<Table>
  <TableHeader>
    <TableRow>
      <TableHead>Age Group/Indication</TableHead>
      <TableHead>Dose</TableHead>
      <TableHead>Frequency</TableHead>
      <TableHead>Notes/Max Daily Dose</TableHead>
    </TableRow>
  </TableHeader>
  <TableBody>
    <TableRow>
      <TableCell>Acute Otitis Media (AOM)</TableCell>
      <TableCell>30 mg/kg</TableCell>
      <TableCell>Single dose</TableCell>
      <TableCell>Maximum single dose 1.5 g</TableCell>
    </TableRow>
    <TableRow>
      <TableCell>AOM, CAP</TableCell>
      <TableCell>10 mg/kg</TableCell>
      <TableCell>Once daily</TableCell>
      <TableCell>Day 1, followed by 5 mg/kg once daily on Days 2–5. Max dose: 500 mg Day 1, 250 mg thereafter.</TableCell>
    </TableRow>
    <TableRow>
      <TableCell>Pharyngitis/Tonsillitis (≥2 years)</TableCell>
      <TableCell>12 mg/kg</TableCell>
      <TableCell>Once daily</TableCell>
      <TableCell>For 5 days. Max daily dose 500 mg.</TableCell>
    </TableRow>
  </TableBody>
</Table>

- Safety and efficacy not established in children under **6 months** for most indications.

## Administration

- May be taken with or without food.
- Do not administer simultaneously with **aluminium- or magnesium-containing antacids**; separate dosing by at least **2 hours**.

## Contraindications

<Callout type='danger'>
- **Hypersensitivity** to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or any product excipients.
- History of **cholestatic jaundice/hepatic dysfunction** associated with prior azithromycin use.
- Concomitant use with **pimozide** due to the risk of QT interval prolongation and serious cardiac arrhythmias.
- History of **QT interval prolongation** (congenital or documented).
- **Electrolyte disturbances** (uncorrected hypokalaemia or hypomagnesaemia).
- Clinically relevant **bradycardia** or **cardiac arrhythmia**.
</Callout>

## Adverse Reactions

- **Common**
  - Gastrointestinal (GI) disturbances: **Diarrhoea** (may be severe), nausea, vomiting, abdominal pain.
  - Headache.

- **Uncommon**
  - Dizziness, somnolence, fatigue.
  - Rash, pruritus (itching).
  - Fungal infections (oral or vaginal candidiasis).
  - Changes in liver function tests.

- **Rare / Serious**
  - **Clostridioides difficile-associated diarrhoea (CDAD)**.
  - **Hepatotoxicity** (severe, potentially fatal).
  - **QT prolongation** and **Torsade de Pointes**.
  - **Allergic reactions**: Angioedema, anaphylaxis, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
  - Exacerbation of **myasthenia gravis**.
  - **Hearing impairment** (usually reversible).

## Pregnancy and Lactation

<Callout>
**Pregnancy:**
- Generally considered acceptable for use when clinically needed.
- Data from observational studies do not show a consistently increased risk of major congenital malformations.
- Use only if benefit outweighs the potential risk.

**Lactation:**

- Passes into breast milk in small amounts.
- Usually considered safe; monitor the infant for gastrointestinal upset (diarrhoea, vomiting) or fungal infections (thrush, rash).
</Callout>

## Sources

- Joint Formulary Committee. **British National Formulary (BNF)**. 87th ed. London: BMJ Group and Pharmaceutical Press; 2024.
- **MIMS (Monthly Index of Medical Specialities)**. Malaysia edition. 2024.
- U.S. Food and Drug Administration (FDA) Approved Drug Label (Zithromax).
- **Drugs.com** Professional Monograph: Azithromycin.
